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Abstract
Background: Publication bias and other reporting bias have been well documented for journal articles, but no
study has evaluated the nature of results posted at ClinicalTrials.gov. We aimed to assess how many randomized
controlled trials (RCTs) with results posted at ClinicalTrials.gov report statistically significant results and whether
the proportion of trials with significant results differs when no treatment effect estimate or p-value is posted.
Methods: We searched ClinicalTrials.gov in June 2015 for all studies with results posted. We included completed
RCTs with a superiority hypothesis and considered results for the first primary outcome with results posted. For
each trial, we assessed whether a treatment effect estimate and/or p-value was reported at ClinicalTrials.gov and
if yes, whether results were statistically significant. If no treatment effect estimate or p-value was reported, we
calculated the treatment effect and corresponding p-value using results per arm posted at ClinicalTrials.gov when
sufficient data were reported.
Results: From the 17,536 studies with results posted at ClinicalTrials.gov, we identified 2823 completed phase 3 or
4 randomized trials with a superiority hypothesis. Of these, 1400 (50%) reported a treatment effect estimate and/or
p-value. Results were statistically significant for 844 trials (60%), with a median p-value of 0.01 (Q1-Q3: 0.001–0.26).
For the 1423 trials with no treatment effect estimate or p-value posted, we could calculate the treatment effect and
corresponding p-value using results reported per arm for 929 (65%). For 494 trials (35%), p-values could not
be calculated mainly because of insufficient reporting, censored data, or repeated measurements over time. For the 929
trials we could calculate p-values, we found statistically significant results for 342 (37%), with a median p-value of 0.19
(Q1-Q3: 0.005–0.59).
Conclusions: Half of the trials with results posted at ClinicalTrials.gov reported a treatment effect estimate and/or
p-value, with significant results for 60% of these. p-values could be calculated from results reported per arm at
ClinicalTrials.gov for only 65% of the other trials. The proportion of significant results was much lower for these
trials, which suggests a selective posting of treatment effect estimates and/or p-values when results are
statistically significant.
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Background
Most patients assume that they are receiving evidence-
based care made by well-informed medical practitioners.
However, reporting bias within peer-reviewed literature
makes that assumption difficult [1, 2]. Evidence of such
reporting bias has been well documented [3–6], with many
studies showing that trials with statistically significant
results are more likely to be published and to be pub-
lished more quickly than those with no statistical differ-
ence [3, 6–8]. Such reporting bias may affect the results
of systematic reviews and meta-analyses toward more
positive results [9, 10] and lead to erroneous decision-
making with serious consequences for patients [11, 12].
To limit reporting bias, the International Committee
of Medical Journal Editors (ICMJE) released a statement
in 2005 that made trial registration a condition for publi-
cation [13–15]. A further step was achieved in 2007 with
the US Food and Drug Administration Amendments
Act (FDAAA 801) requiring phase 2–4 trials of FDA-
approved drugs, devices, or biologics to post results on
the federally funded registry ClinicalTrials.gov within
1 year of completion [16, 17]. According to the law, “a
table of values for each of the primary and secondary
outcome measures for each arm of the clinical trial, in-
cluding the results of scientifically appropriate tests of
the statistical significance of such outcome measures”
should be posted [18]. However, it seems that many tri-
als with results posted fail to report a an estimate of
treatment effect or p-value.
In this study, we aimed to assess how many superiority
clinical trials with results posted at ClinicalTrials.gov re-
port statistically significant results and whether the pro-
portion of significant results differed for trials with no
treatment effect estimate or p-value posted.
Methods
Data sources
On 2 June 2015, one of the authors (EGB) searched Clini-
calTrials.gov for “Studies with Results” in the Study Re-
sults field, then downloaded all records corresponding to
these studies as excel and xml files. There was no limit on
date. xml files were handled with R version R 3.2.3 (R
Foundation for Statistical Computing, Vienna, Austria;
https://www.R-project.org/) with the xml package.
Identification of completed phase 3 or 4 clinical trials
with a superiority hypothesis
Trials reported as “phase 3” or “phase 4” in the phase
field, as “randomized” in the study design field, and as
“completed” in the recruitment field were considered for
inclusion. Trials not reporting these elements were ex-
cluded. We identified the number of arms reported in
the study results and excluded single-arm trials as well
as trials involving three or more arms so as to focus on
comparisons between an experimental intervention and
a control. We excluded non-inferiority and equivalence
trials, which were identified if the keywords “non-infer-
iority,” “non-inferior,” “equivalence,” “bioequivalence,”
“bio-equivalence,” or “equivalent” were present in the
following fields: study design, endpoint classification, or
study results. We manually verified that each trial ex-
cluded on the basis of these criteria met the definition
of a non-inferiority trial (i.e., aiming to show that an
experimental intervention is non-inferior to a control
one) or equivalence trial (i.e., aiming to show that two
interventions have therapeutic equivalence [19, 20]).
We also excluded pharmacokinetic trials reported as a
“bio-equivalence study” or “pharmacokinetics/dynamics
study” in the endpoint classification field or based on
information reported in the study results. We consid-
ered all other trials as superiority trials (i.e., aiming to
show a statistical difference between two interventions
[20]) and included them. The selection process was
done by one reviewer (EGB) and checked by a second
reviewer (JS). Any discrepancies were resolved by a
third reviewer (AD).
Extraction of data from ClinicalTrials.gov
The following characteristics were extracted from the re-
cords downloaded from ClinicalTrials.gov:
1. General characteristics: we collected the phase of
the trial (phase 3 or 4), type of intervention assessed
(e.g., drug, biological, or device), type of control
(i.e., placebo, no treatment, or active control),
sponsor, and collaborators. We considered that
there was an industry sponsorship if the sponsor
or one of the collaborators was industry. We also
extracted sample size and primary completion
date (i.e., date of final collection for the primary
outcome).
2. Location: we collected the countries where the trial
was conducted and whether the trial was conducted
in a single country and the number of centers
involved.
3. Results posted: we collected the date when results
were first received and whether the study was likely
subject to the FDAAA. This characteristic is based
on an algorithm developed by the US National
Library of Medicine. Then, for the first primary
outcome reported in the Results section, we
collected whether a treatment effect estimate and/or
p-value was reported and, if yes, we extracted them.
Reporting of statistically significant results for the first
primary outcome reported
For each trial with a treatment effect estimate and/or
p-value reported, we evaluated whether results reported
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were statistically significant or not. To do so, we relied
on the p-value reported at ClinicalTrials.gov and con-
sidered p-values <0.05 as statistically significant. Five
percent has been the most commonly used threshold
for statistical significance in clinical intervention re-
search [21]. When only a measure of treatment effect
with 95% confidence interval (CI) was reported, we de-
rived the p-value from the 95% CI using the formula re-
ported by Altman and Bland [22].
Calculation of p-values for trials with no treatment effect
estimate or p-value reported
For trials with no treatment effect estimate or p-value re-
ported, we calculated whenever possible the treatment ef-
fect estimate and corresponding p-value using the results
per arm posted at ClinicalTrials.gov. This calculation was
possible only for binary and continuous outcomes when
sufficient data were reported at ClinicalTrials.gov. For
binary outcomes, we calculated relative risk with 95%
CI and the corresponding p-value from the number of
events and number of participants analyzed reported
per arm. For continuous outcomes, we calculated
mean difference with 95% CI and the corresponding
p-value from the mean and standard deviation (SD) or
standard error (SE), which we transformed to SD as
well as the number of participants analyzed reported
per arm.
Extraction of results per arm from ClinicalTrials.gov and
calculation of treatment effect estimate with 95% CI and
the corresponding p-value was systematically performed by
two reviewers working independently (JS and CR) using
Revman 5.3 (Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2014). Then, all results were
compared and any disagreement was resolved by consensus
with the help of a senior researcher (AD) if needed. We also
considered a p-value <0.05 as statistically significant.
Calculation of treatment effect estimate and corre-
sponding p-value was not possible for censored outcomes
(e.g., progression-free survival), repeated measurements of
the outcome over time (e.g., change in mean bone mineral
density from baseline assessed at 12, 24, and 36 months),
other situations for which there were several observa-
tions or events per patient because these situations re-
quired individual patient data, or when there was no
event in both groups.
Statistical analysis
Categorical variables were described with frequencies
(percentages) and quantitative variables with median
(Q1-Q3). To assess the statistical significance of the
results, we focused on p-values rather than on treat-
ment effect estimates with 95% CI, and graphically
represented the density plots of p-values for trials by
whether a treatment effect estimate and/or p-value
was reported or not. For this, we considered p-values
<0.0001 equal to 0.0001.
We aimed to identify trial characteristics associated
with reporting a p-value <0.05 for the first primary
outcome at ClinicalTrials.gov. To do, so, we first
compared trial characteristics by whether results
were reported to be statistically significant or not
using chi-square tests for categorical variables and
Wilcoxon tests for continuous variables. Then, we
used a multivariate logistic regression model to iden-
tify factors independently associated with the report-
ing of statistically significant results. All variables
that were statistically significant on univariate ana-
lyses were entered into multivariate analysis except
single-center, which was closely related to single-
country status.
Statistical analysis involved use of SAS 9.3 (SAS Inst.,
Cary, NC, USA). The density plot was created with R
3.2.3 (R Foundation for Statistical Computing) using a
syntax provided in a previous article [23].
Results
Identification of completed randomized trials with a
superiority hypothesis
Figure 1 shows the selection process. From the 192,175
studies registered at ClinicalTrials.gov on 2 June 2015,
17,536 had results posted, with 9640 (55%) likely to be
subject to the FDAAA. We identified 2823 completed
phase 3 or 4 randomized trials with a superiority
hypothesis.
Reporting of treatment effect estimate and/or p-value at
ClinicalTrials.gov
Among the 2823 eligible trials, 1400 (50%) had a treat-
ment effect estimate and/or p-value reported at Clinical-
Trials.gov, and 1423 trials (50%) had only results per
arm reported. Characteristics of trials by whether a treat-
ment effect estimate and/or p-value was reported or not
are reported in Table 1. Briefly, as compared with trials
with no treatment effect estimate or p-value reported,
those with a treatment effect estimate and/or p-value re-
ported were more likely to be phase 3 trials (68% versus
51%), to have an inactive comparator (59% versus 36%),
to have an industry sponsorship (83% versus 74%), to in-
volve several countries (41% versus 21%) and several
centers (66% versus 49%), to be subject to the FDAAA
(68% versus 59%), and to have a larger median sample
size (270 versus 156).
Reporting of statistically significant results for the first
primary outcome
When a treatment effect estimate and/or p-value was
reported (N = 1400 trials), results were reported as
Dechartres et al. BMC Medicine  (2016) 14:192 Page 3 of 10
Fig. 1 Flow chart of the selection of trials. RCT randomized controlled trial, SD standard deviation
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statistically significant for 844 trials (60%), with a
median p-value of 0.01 (Q1-Q3: 0.001–0.26) (Fig. 2).
For trials with no treatment effect estimate or p-value
reported at ClinicalTrials.gov (N = 1423), we could
calculate treatment effect estimate and the corre-
sponding p-value for 929 (65%). From data posted at
ClinicalTrials.gov, p-values could not be calculated for
494 trials (35%), mainly because of the reporting of
percentages only for binary outcomes (n = 187), no
reporting of mean (±SD) for continuous outcomes (n
= 95), censored data (n = 61), and repeated measure-
ments over time (n = 52). Characteristics did not dif-
fer between trials for which we could calculate p-
values and those with no treatment effect estimate or
p-value reported (Appendix). Among the 929 trials
for which we could calculate p-values, results were
statistically significant for 342 (37%), with a median
p-value of 0.19 (Q1-Q3: 0.005–0.59) (Fig. 2).
Factors associated with reporting statistically significant
results for the first primary outcome
Table 2 compares trial characteristics by whether statistically
significant results were reported or not. Trials with signifi-
cant results reported were more likely to be phase 3 trials
(74% versus 53%, p < 0.0001), to have an inactive compara-
tor (64% versus 40%, p < 0.0001), to have an industry spon-
sorship (totally or partially) (88% versus 74%, p < 0.0001), to
be subject to the FDAAA (70% versus 61%, p < 0.0001), and
to have a larger sample size or to be a multicenter trial in-
volving several countries than those reporting a p-value
≥0.05 or not reporting treatment effect estimate or p-value.
Table 1 Characteristics of completed phase 3 or 4 randomized clinical trials with results posted and a superiority hypothesis by
whether a treatment effect estimate and/or p-value is reported at ClinicalTrials.gov
Characteristics Categories Trials with treatment effect
estimate and/or p-value reported
(N = 1400)
Trials with no treatment effect
estimate or p-value reported
(N = 1423)
Phase of the study Phase 3 948 (68) 728 (51)
Phase 4 452 (32) 695 (49)
Intervention type Drug 1088 (78) 1014 (71)
Mixed interventions 180 (13) 148 (10)
Biological 48 (3) 96 (7)
Device 40 (3) 97 (7)
Other 44 (3) 68 (5)
Control group Placebo or no treatment 822 (59) 516 (36)
Active treatment 578 (41) 907 (64)
Sponsorship Industry totally or partly 1162 (83) 1055 (74)
Academic only 238 (17) 368 (26)
Countries Single country 646 (46) 982 (69)
Multiple countries 568 (41) 292 (21)
Not reported 186 (13) 149 (10)
Location At least one site in the USA 846 (61) 822 (58)
No site in the USA 368 (26) 452 (32)
Not reported 186 (13) 149 (10)
Subject to the FDAAA Yes 951 (68) 843 (59)
No 377 (27) 556 (39)
Not reported 72 (5) 24 (2)
Centers Multicenter 929 (66) 696 (49)
Single center 285 (20) 578 (41)
Not reported 186 (13) 149 (10)
Sample size Median (Q1-Q3) 270 (116–520) 156 (60–378)
Time to results first received at
ClinicalTrials.gov (month)
Median (Q1-Q3) 13.5 (11.7–26.4) 17.1 (12.0–32.3)
Data are presented as n (%) unless indicated. FDAAA US Food and Drug Administration Amendments Act, IQR Q1-Q3
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On adjusted multivariate analysis, reporting statisti-
cally significant results at ClinicalTrials.gov for the first
primary outcome was associated with being a phase 3
trial (odds ratio [OR] = 1.68, 95% CI 1.38–2.04), having
an inactive comparator (OR = 2.19, 95% CI 1.83–2.61),
having an industry sponsorship (OR = 1.57, 95% CI
1.22–2.03), and involving multiple countries (OR = 1.58,
95% CI 1.29–1.93) (Table 3).
Discussion
Nearly half of the studies with results posted at Clini-
calTrials.gov are not required to do so as they do not
seem to be subject to the FDAAA. Nevertheless, more
attention should be paid to having more complete
and transparent results posted. Only half of the com-
pleted trials with results posted at ClinicalTrials.gov
report a treatment effect estimate and/or p-value for
the first primary outcome posted, with 60% of these
trials reporting significant results. In contrast, the propor-
tion of trials with significant results seemed much lower
when no treatment effect estimate or p-value was re-
ported. Factors independently associated with reporting
statistically significant results at ClinicalTrials.gov were
being a phase 3 trial, using an inactive comparator, hav-
ing industry sponsorship, and involving multiple
countries.
ClinicalTrials.gov is the most widely used clinical trial
registry worldwide, with studies registered from 190
countries, and for now it is the only one allowing stan-
dardized posting of results [17, 18]. Clinical.Trials.gov
represents a crucial source of information on trial re-
sults. Previous studies showed that it allows access to
results not yet published and to more complete results
than in corresponding published articles [24–26]. A re-
cent study has compared results posted at Clinical-
Trials.gov to corresponding FDA reports for new drug
approval trials and found large concordance between
both sources [27].
In this study, we found that results of many trials are
posted although not required, because nearly half of the
trials with results posted did not seem to be subject to
the FDAAA according to the algorithm developed by the
US National Library of Medicine. This is encouraging
and highlights a willingness to give access to study re-
sults for the sake of transparency and not only because
it is compulsory.
Fig. 2 Density plot of p-values for trials with results for the first primary outcome posted at ClinicalTrials.gov. Left: 1400 trials with treatment effect
estimate and/or p-value reported. Right: 929 trials with no treatment effect estimate or p-value reported (p-value calculated from data reported
per arm at ClinicalTrials.gov). The lowest 25 quantiles are not visible because of clustering at p = 0.001 and p = 0.005, respectively. The white circle
indicates the median p-value
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Table 2 Characteristics of completed phase 3 or 4 randomized clinical trials with a superiority hypothesis according to whether
significant results (i.e., p-value <0.05 or treatment effect with 95% CI not including the null value) were reported at ClinicalTrials.gov
Characteristics Categories Trials with significant
results reported
(N = 844)
Trials with non statistically significant




Phase of the study Phase 3 622 (74) 1054 (53) <0.0001
Phase 4 222 (26) 925 (47)
Intervention type Drug 675 (80) 1427 (72) <0.0001
Mixed interventions 97 (11) 231 (12)
Biological 29 (3) 115 (6)
Device 22 (3) 115 (6)
Other 21 (2) 91 (5)
Control group Placebo or no treatment 543 (64) 795 (40) <0.0001
Active treatment 301 (36) 1184 (60)
Sponsorship Industry totally or partly 744 (88) 1473 (74) <0.0001
Academic only 100 (12) 506 (26)
Countries Single country 361 (43) 1267 (64) <0.0001
Multiple countries 353 (42) 507 (26)
Not reported 130 (15) 205 (10)
Location At least one site in the USA 493 (59) 1175 (59) 0.003
No site in the USA 221 (26) 599 (30)
Not reported 130 (15) 205 (10)
Subject to the FDAAA Yes 588 (70) 1206 (61) <0.0001
No 201 (24) 732 (37)
Not reported 55 (6) 41 (2)
Centers Multicenter 581 (69) 1044 (53) <0.0001
Single center 133 (16) 730 (37)
Not reported 130 (15) 205 (10)
Sample size Median (Q1-Q3) 305 (139–541) 179 (62–405) <0.0001
Time to results first received at
ClinicalTrials.gov (month)
Median (Q1-Q3) 13.0 (11.6–26.3) 16.5 (12.0–30.9) <0.0001
Data are presented as n (%) unless indicated. FDAAA US Food and Drug Administration Amendments Act, Q1-Q3: Quartile 1-Quartile 3
Table 3 Factors independently associated with reporting statistically significant results (i.e., reporting a p-value <0.05 or treatment
effect with 95% CI not including the null value) for the first primary outcome posted at ClinicalTrials.gov for completed superiority
clinical trials
Characteristics Adjusted OR (95% CI) p-value
Phase of the trial Phase 3 versus 4 1.68 (1.38–2.04) <0.0001
Intervention Drug versus other 1.20 (0.97–1.48) 0.10
Control group Inactive versus active 2.19 (1.83–2.61) <0.0001
Sponsorship Industry (totally or partially) versus academic 1.57 (1.22–2.03) 0.0005
FDAAA Subject versus not subject 1.15 (0.94–1.41) 0.17
Countries Multiple countries versus single country 1.58 (1.29–1.93) <0.0001
Not reported versus single country 1.50 (1.14–1.98) 0.004
Sample size For an increase of 100 patients 1.002 (0.99–1.005) 0.20
OR odds ratio, CI confidence interval, FDAAA US Food and Drug Administration Amendments Act
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Several methodological studies have evaluated com-
pliance with the FDAAA requiring posting of results
for applicable trials [28–30] but few have looked at the
nature of the results posted. Only one research note
evaluated an association between changes in primary
outcomes and reporting a significant result [31].
Our results show that, despite the FDAAA require-
ment to post results from scientifically appropriate
tests of statistical significance, only half of the trials
with results posted reported a p-value and/or a meas-
ure of treatment effect. For the other trials, we
attempted to calculate treatment effect estimate and
p-values but this was not possible for 35% of trials,
mainly because of insufficient reporting or because in-
dividual patient data were required (i.e., for analysis of
censored outcomes or repeated measurements over
time). Therefore, for about one third of trials, system-
atic reviewers may be unable to use the results re-
ported at ClinicalTrials.gov when treatment effect
estimates or p-values are not reported. Our results
also suggest that the proportion of trials with signifi-
cant results differs between trials reporting or not a
treatment effect estimate and/or p-value. Although we
could not calculate treatment effect and correspond-
ing p-values for all trials not reporting these, our re-
sults suggest a much lower proportion of trials with
significant results when no treatment effect estimate
or p-value is reported. These results may reflect a
selective posting of treatment effect estimate and/or
p-value when results are statistically significant. This
lack of transparency may have consequences when
interpreting the results posted at ClinicalTrials.gov
because physicians and decision-makers may be
more likely to rely on trials with p-values already
reported.
We identified some factors associated with reporting
significant results at ClinicalTrials.gov. Reporting of sig-
nificant results for the first primary outcome posted
were more frequent for trials sponsored by industry than
academic sources, which is consistent with previous
studies finding that industry trials are more likely than
public trials to report significant results in published ar-
ticles [32, 33] and at ClinicalTrials.gov [31]. In addition,
reporting of significant results was also more common
for phase 3 trials and for trials with an inactive control.
This finding is not surprising for trials with inactive
control treatment because treatment effect estimates
are expected to be higher in this situation than when
the experimental intervention is compared to an active
treatment.
This study has important implications. It highlights
the importance of having complete results posted,
including the posting of treatment effect estimate
and/or p-value, to avoid any misinterpretation about
the benefits of interventions. Because of the poor
compliance with these requirements, it becomes ne-
cessary to improve their implementation. Systematic
checking of results posted and automatic mailing to
responsible parties may help improve the complete-
ness of results posted. A recent article showed that
sending emails to responsible parties of completed
trials that do not comply with the FDAAA legal re-
quirement to post results significantly improved the
posting rate at 6 months [34]. In April 2014, the
European Union voted to adopt the Clinical Trials
Regulation, which requires the registration of all
clinical trials conducted in Europe and the posting
of trial summary results in the European Clinical trials
Database (EudraCT) within 1 year after trial completion
[35, 36]. This is a crucial step toward more transparency
and this initiative should take advantage of the body of
literature available for ClinicalTrials.gov and compli-
ance with the FDAAA during the implementation
process.
Our study has some limitations. We only looked at
the first primary outcome with results posted, so our
study is not representative of all results posted at Clini-
calTrials.gov. For trials with no treatment effect
estimate or p-value reported, we attempted to calculate
the treatment effect and corresponding p-values from
data reported per arm, adopting the viewpoint of sys-
tematic reviewers. However, we could not do this for
about one third of trials with no treatment effect esti-
mate or p-value reported because of insufficient ele-
ments reported or because the data were repeated
measures or censored, situations for which individual
participant data are necessary. Although there was no
difference between trials for which we could calculate a
p-value and those with no treatment effect estimate
and/or p-value, our results cannot be extrapolated to all
trials with no treatment effect estimate or p-value re-
ported. Finally, we focused on results reported at Clini-
calTrials.gov and did not determine whether results
had been published or not.
Conclusions
Only half of completed trials with results posted at
ClinicalTrials.gov had a treatment effect estimate and/
or p-value reported for the first primary outcome, with
significant results in 60% of these. The proportion of
trials with significant results seemed much lower when
no treatment effect estimate or p-value is reported,
which may suggest a selective posting of treatment
effect estimate and/or p-value when results are statis-
tically significant. More efforts should be expended
to improve the transparency in posting results at
ClinicalTrials.gov.
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